NFE2L2 and cancer: Across the entire proteomic compendium tumor dataset, assessment of genes within pathways demonstrated a high number of somatic alterations (small mutation or CNA) involving chromatin modification (73.4% of 1597 tumors involving 12 cancer types with small mutation and CNA data available), p53/Rb-related (73.1%), SWI/SNF complex (70.0%), PI3K/AKT/mTOR (69.2%), Receptor Tyrosine Kinase signaling (RTK, 55.0%), Wnt/beta-catenin (51.8%), MYC/MYCN (39.6%), NRF2 (8.2%), and Hippo signaling (36.3%) (Fig. 7a).